Latest News and Updates

2019 ADS-Abbott Travel Grants to ADA
The Australian Diabetes Society is pleased to call for applications for the 2019 ADS-Abbott Travel Grants to attend the American Diabetes Association meeting to be held in San Francisco, California, USA from 7-11 June 2019. The merit-based travel grant will be up to the value of A$2,000 and awarded to PhD student applicants.

To be eligible, applicants must:

To apply, please submit:

The travel grant applications should be directed to Dr Sof Andrikopoulos, CEO at the Australian Diabetes Society on email ceo@diabetessociety.com.au and include the grant name in the subject line of the email.

Applications Closing Date: Monday 29 April 2019

Applications will be peer-reviewed. The travel grant is merit based, and we reserve the right not to award the funds in this round if there are no qualifying applicants of suitable calibre.  The ADS is very grateful to Abbott Australasia for providing support of the travel grant to ADS members.


2019 ADS Kellion Award

The Kellion Foundation and the Australian Diabetes Society invite applications for the Award for an Australian who has made an outstanding contribution in diabetes research, clinical or service areas in Australia.  This is an annual award that commenced in the year 2000 and is the premier award bestowed on an individual by the Australian Diabetes Society.

Nominations are now called for this Award which will be considered by a review committee consisting of the Australian Diabetes Society Council as well as prominent Australian diabetes experts and if appropriate international referees.  Nominations may be self-initiated, initiated by colleagues or by organisations.

The recipient of the Kellion Award must be a financial ADS member and will be required to deliver the ADS Kellion Plenary Lecture at the Australian Diabetes Society/Australian Diabetes Educators Association Australasian Diabetes Congress to be held at the International Convention Centre, Sydney, NSW from 21 - 23 August 2019.  The Award will include a return business class airfare to the meeting, accommodation for the duration of the meeting, registration, and a commemorative plaque.  There is also a A$10,000 honorarium.

Nominations should include a letter (not exceeding 2 pages) clearly stating the basis of the nomination and a full curriculum vitae of the nominee.  Nominations made in the previous years have been retained and will be considered also.

Nominations Closing Date: Monday 6 May 2019

Please forward nominations or for further enquires to:-

Dr Sof Andrikopoulos
Australian Diabetes Society
145 Macquarie St
SYDNEY NSW 2000
Ph: 02 9256 5462
Email: ceo@diabetessociety.com.au

Previous recipients of this prestigious award include:  Len Harrison (2000), Don Chisholm (2001), George Jerums (2002), Paul Zimmet (2003), Tim Welborn (2004), Mark Cooper (2005), David James (2006), Ted Kraegen (2007), Martin Silink (2008), Michael Horowitz (2009), Dennis Yue (2010), Frank Alford (2011), Joseph Proietto (2012), Peter Colman (2013), Timothy Davis (2014), Stephen Colagiuri (2015), Kerin O'Dea (2016), Mark Febbraio (2017), Jonathan Shaw (2018)


2019 Best ADS Clinical Presentation Award in memory of Dr Paul Lee
The Best ADS Clinical Presentation Award in memory of Dr Paul Lee is to the value of A$1,250. The finalists will be categorised into Clinical Research and the award will be given to the best oral presentation by an ADS member at the ADS/ADEA Australasian Diabetes Congress in Sydney as judged by peer review and a committee appointed by the ADS Council. 2019 is the inaugural year of this annual award.

Eligibility is as follows:

1. A financial member of the ADS for 12 months at the time of application
(Member must have joined as an approved member of ADS from May 2018 and Paid subs for 2019)
2. Applicant must be a mid-career clinical researcher (4-10 years post-doctoral)
3. Each applicant must provide a supporting statement indicating that the work presented is substantially the candidate’s own work
4. Finalist applicants must present work of abstract submitted for the conference; if not they will be in-eligible to receive the award

6-8 applicants will be selected from abstracts to present in the award session.

ADS ASM Awards Application Form

To apply:
Please click on 'ADS ASM Awards Application Form' and complete the online application form. Please ensure that you have uploaded your supporting documentation. You must tick the box during abstract submission. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au

Applications Closing Date: Monday 13 May 2019


2019 ADS Australasian Diabetes Congress Awards
A number of awards and grants are available for ADS members attending the ADS/ADEA Australasian Diabetes Congress in Sydney, NSW.

Please ensure that you indicate (tick the appropriate boxes) during the abstract submission process via the ADC website; if you would like to be considered for any of the ADS Awards.

Please see below for all ADS ASM Awards and Grants on offer for 2019:-


ADS POSTER AWARDS

ADS Poster Awards for both Basic Science and Clinical Research will be on offer during the ADS/ADEA Australasian Diabetes Congress in Sydney, NSW. ADS Poster Awards are to the value of A$500 each.

Eligibility is as follows:
1. A financial member of the ADS (Paid subs for 2019)
2. Applicant must be an early career researcher
3. You must be standing by your poster at the time of the poster session
4. Each applicant must provide a supporting statement including one signed by his/her supervisor or department head, indicating that the work presented is substantially the candidate’s own work

To apply: Please click on 'ADS ASM Awards Application Form' and complete the online application form. Please ensure that you have uploaded your supporting documentation. You must tick the box during abstract submission. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au

Applications Closing Date: Monday 13 May 2019

ADS ASM Awards Application Form

 

ADS-PINCUS TAFT YOUNG INVESTIGATOR AWARD

The ADS-Pincus Taft Young Investigator Award is to the value of A$2000. The finalists will be categorised into Basic Science and the award will be given to the best oral presentation by a junior ADS member at the ADS/ADEA Australasian Diabetes Congress in Sydney as judged by peer review and a committee appointed by the ADS Council.

Eligibility is as follows:

1. A financial member of the ADS for 12 months at the time of application
(Member must have joined as an approved member of ADS from May 2018 and Paid subs for 2019)
2. Applicant must not be more than 2 years beyond the award of a doctoral degree (PhD, MD) or fellowship (FRACP)
3. Each applicant must provide a supporting statement including one signed by his/her supervisor or department head, indicating that the work presented is substantially the candidate’s own work
4. Previous winners of this award are in-eligible to apply
5. Finalist applicants must present work of abstract submitted for the conference; if not they will be in-eligible to receive the award

6-8 applicants will be selected from abstracts to present in the ADS-Pincus Taft Young Investigators Session.

To apply: Please click on 'ADS ASM Awards Application Form' and complete the online application form. Please ensure that you have uploaded your supporting documentation. You must tick the box during abstract submission. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au

Applications Closing Date: Monday 13 May 2019

 

ADS PRESIDENT'S YOUNG INVESTIGATOR AWARD

The ADS President's Young Investigator Award is to the value of A$2000. The finalists will be categorised into Clinical Research and the award will be given to the best oral presentation by a junior ADS member at the ADS/ADEA Australasian Diabetes Congress in Sydney as judged by peer review and a committee appointed by the ADS Council.

Eligibility is as follows:

1. A financial member of the ADS for 12 months at the time of application
(Member must have joined as an approved member of ADS from May 2018 and Paid subs for 2019)
2. Applicant must not be more than 2 years beyond the award of a doctoral degree (PhD, MD) or fellowship (FRACP)
3. Each applicant must provide a supporting statement including one signed by his/her supervisor or department head, indicating that the work presented is substantially the candidate’s own work
4. Previous winners of this award are in-eligible to apply
5. Finalist applicants must present work of abstract submitted for the conference; if not they will be in-eligible to receive the award

6-8 applicants will be selected from abstracts to present in ADS Presidents Young Investigators Session.

To apply: Please click on 'ADS ASM Awards Application Form' and complete the online application form. Please ensure that you have uploaded your supporting documentation. You must tick the box during abstract submission. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au

Applications Closing Date: Monday 13 May 2019

ADS ASM Awards Application Form


2019 ADS Ranji and Amara Wikramanayake Clinical Diabetes Research Award

This Mid-Career Award supporting the career of a clinical diabetes researcher has been made possible by the generosity of Dr Ranji Wikramanayake, a long standing member of the Australian Diabetes Society.

The Australian Diabetes Society invites applications for a Mid-Career Diabetes Research Award from endocrinology/diabetes clinicians who are members of the Australian Diabetes Society (ADS) and are between 6-15 years' post-doctoral degree.  Applications can be nominated by financial members of the ADS or by self-nomination. 

The award is to recognise significant contributions to diabetes research by a clinician and to support further advancement of those achievements. 

The successful candidate will deliver the ADS Ranji and Amara Wikramanayake Clinical Diabetes Award Lecture at the 2019 ADS/ADEA Australasian Diabetes Congress to be held at the International Convention Centre from 21 to 23 August 2019. In addition, the awardee will be required to provide a written report on their further achievements (projects, presentations, publications, funding, community engagement) within 18 months of accepting the award.

The award is for A$40,000 and will be presented at the conclusion of the award lecture along with a commemorative plaque.

The selection criteria are:

  • Is a clinician who has provided significant contributions to diabetes research
  • Is a financial member of the ADS (Paid to 2019)
  • Is between 6-15 years post-doctoral degree
  • Is available to give the award lecture at the ADS/ADEA Australasian Diabetes Congress in 2019

Applications, accompanied by a full curriculum vitae, are now invited and should be in the form of a letter not exceeding 2 pages outlining the applicant’s suitability for the award.

Applications should be emailed to Dr Sof Andrikopoulos, ADS CEO at ceo@diabetessociety.com.au

Applications Closing Date: Monday 27 May 2019


2019 ADS Jeff Flack Diabetes Data Award
The Australian Diabetes Society invites nominations for the 2019 ADS Jeff Flack Diabetes Data Award for an Australian researcher who has made an outstanding contribution to Diabetes data collection in Australia. The Award will be considered by a review committee consisting of prominent Australian diabetes researchers with the option to co-opt international referees.  The nominee must be a financial member of the ADS and have been a member for at least 12 months at the time of their nomination for this award.  At least one of the Nominator/s must be an ADS member and nominations can be self-initiated or initiated by colleagues.

Categories of merit include:

    • Multiple / Significant / Substantial Publications (or In Press) involving data collection, collation, analysis and reporting (beyond ‘routine day-to-day’ minimum dataset collection);
    • Something ‘Novel’ regarding data collection / reporting – development of data systems;
    • Substantial contribution to data issues (attendance / chair of Committee(s) on data issues – developing standards etc);
    • List the best 5 or 10 relevant publications;
    • Highlight all relevant publications in your CV.
Nominations should include a letter (not exceeding 2 pages) clearly stating the basis of the nomination and a full curriculum vitae and be sent to:


Dr Sof Andrikopoulos
Chief Executive Officer
Australian Diabetes Society
145 Macquarie Street
SYDNEY   NSW   2000
Fax:  02-9252 3668
Email: ceo@diabetessociety.com.au 

Further enquiries can be directed to Dr Sof Andrikopoulos, CEO, ADS on telephone (02) 9256 5462 or email ceo@diabetessociety.com.au

Nominations Closing Date: Monday 24 June 2019


2019 ADS Lifetime Achievement Award
Eligibility
The Lifetime Achievement Award recognises an individual who has:

  1. An established history of distinguished service to education, clinical practice and/or research and training in diabetes
  2. Made a lasting contribution to diabetes
  3. Exhibited leadership and mentorship in diabetes research and/or clinical practice on a state, national and/or international level

Selection of the nominee is made on the basis of the candidate's significant, fundamental contributions to diabetes (whether in research, clinical practice, leadership, mentorship or other); the lasting impact of these contributions to the sector; and the demonstration of a lifetime commitment to diabetes.

Nominees must have:

  1. Made a positive impact to diabetes [at either state/territory or national level]
  2. The respect of professional peers
  3. General acknowledgement as having reached a pinnacle of their profession
  4. Demonstrated, over an extended period of time, a contribution which has included either research and/or clinical practice, professional leadership and service to the diabetes community
  5. Held positions of leadership
  6. Personal integrity
  7. On-going membership with the ADS

Nominees will be recognised and the winner of the award will be announced at the Annual General Meeting held at ADS/ADEA Australasian Diabetes Congress each year.

Nomination process
Please submit two letters of recommendation including a full curriculum vitae of the nominee to the ADS CEO, Dr Sof Andrikopoulos via email: ceo@diabetessociety.com.au One letter of recommendation must be by a financial member of the ADS.

Nominations Closing Date: Monday 1 July 2019



2019 ADS Australasian Diabetes Congress Travel Grants to Sydney, NSW
A number of ADS Travel Grants will be awarded to junior investigators who have an abstract accepted for presentation at the ADS/ADEA Australasian Diabetes Congress in Sydney. The number and size of grants will be determined according to the number and suitability of applications and the funds available. Applications will be prioritised using abstract review scores. It is anticipated that the awards will represent a substantial contribution to the individual's travel costs to the meeting.

Eligibility is as follows:
1. A financial member of the ADS for 12 months at the time of application
(Member must have joined as an approved member of ADS from June 2018 and Paid subs for 2019)
2. In training for a higher degree eg. PhD, MD, fellowship or medical specialty
3. Supported by a statement from the candidate's supervisor or department head indicating the nature of their present position and the availability of other sources of financial support for their travel to the Meeting
4. Travel Grants will be made directly to the member and not institution

Note: Applicants must not be in receipt of a travel grant from any other body to attend the ADS/ADEA Australasian Diabetes Congress or a meeting in association with the ADS/ADEA ADC.

Applications Closing Date: Monday 8 July 2019


To apply:
Please click on 'Apply for ADS Travel Grant' below and complete the online application form and please ensure that you upload your supporting documentation. The successful applicants will be advised in writing one week prior to the meeting and travel grants will be paid following the ADC. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au

Apply for ADS Travel Grant and Upload Supporting Documentation




Diabetic Foot Australia is moving to the Australian Diabetes Society

We are delighted to announce that with the conclusion of the Wound Management Innovation Cooperative Research Centre (Wound CRC) this month, the Australian Diabetes Society (ADS) will take Diabetic Foot Australia (DFA) into its stable of national diabetes clinical and research programs from the 1st July 2018. Read Media Release (Posted 20 June 2018).

Launched by the Wound CRC in 2015, Diabetic Foot Australia has since become the national multi-disciplinary advocacy body for the prevention, care and research of this prevalant disease. We thank the Wound CRC for their vision, support and investment in establishing DFA and continuing in partnership with Wound Innovations as the Wound CRC's successor.

DFA look forward to working with Dr Sof Andikopoulos and his expert team at ADS in accelerating DFA's work and Australia's progression to ending avoidable amputations in a generation. By combining the well-established reputation of ADS as the peak national diabetes body for scientific and medical sectors, with our engaged national diabetic foot community, we can drive further colloborations, research, education and most importantly, advocacy for patients.

For further exciting DFA activities to be released soon, please visit the DFA website at www.diabeticfootaustralia.org


RACGP & ADS Joint Clinical Position Statement on Emergency Management in Primary Care

Emergency management of hyperglycaemia in primary care was developed by the RACGP and the Australian Diabetes Society (ADS) to raise clinical awareness of hyperglycaemic emergencies in primary care by:

  • Identifying clinically important patient presentations and risk factors

  • Ensuring management of hyperglycaemic emergencies is optimised to prevent serious outcomes

This document should be read in conjunction with the relevant management flow charts (Figures 1 and 2), which provide information for the management of hyperglycaemic emergencies before patients arrive at hospital. This position statement should integrate with, but not replace, existing sick day, ambulance and hospital-based management protocols. Clinicians should consult existing local/regional or health pathways/protocols for inpatient management.

It is important to note this statement does not replace existing diagnostic guidelines for routine (non-emergency) presentations, and should not be used for evaluating hyperglycaemia associated with pregnancy where specialist advice on assessment and management must be sought. Download the jointly-produced RACGP and Australian Daibetes Society clinical Position Statement which aims to assess and manage hyperglycaemic emergencies and prevent adverse outcomes - PDF (Posted: May, 2018)


Subsidised Continuous Glucose Monitoring Products for Young Australians

From 1 April 2017, the Australian Government will provide fully subsidised continuous glucose monitoring (CGM) products to eligible children and young people aged under 21 years with type 1 diabetes.

Children and young people who experience significant challenges in managing their blood glucose levels, particularly those who have difficulty identifying symptoms of hypoglycaemia, will benefit the most from CGM technology.

This initiative allows families and children to better self-manage their blood glucose levels, reducing visits to emergency departments and missed school days.

Continuous glucose monitors will alert users or their parents/carers if glucose levels are getting too low or too high without the need for continuous finger prick tests, reducing stress and anxiety for the child and young person and their family.

To be eligible, the child or young person will need to be assessed by an authorised health professional to determine if they meet specific criteria and to ensure that the use of CGM is a suitable part of their diabetes management plan.

The authorised health professionals for CGM assessment are endocrinologists, credentialled diabetes educators, and other health professionals specialising in diabetes (physicians, paediatricians or nurse practitioners).

An expert CGM Advisory Group, including endocrinologists, credentialed diabetes educators, consumer experts and other diabetes stakeholder groups, has advised that the best clinical outcomes are achieved when CGM is used as part of an ongoing diabetes management plan. Authorised health professionals will also play a key role in assisting in the set up and operation of CGM devices for eligible children and young people not currently using CGM.

The Continuous Glucose Monitoring Eligibility Assessment form is available at www.ndss.com.au/cgm.

Further information about access to CGM products through the NDSS, please visit www.health.gov.au/ndss-cgm. You can also call the NDSS Helpline on 1300 136 588. Download the CGM Flow Chart for Health Professionals - PDF


ADS Position Statement on Insulin-requiring diabetes and recreational diving

Mervyn Kyi, Barbora Paldus, Natalie Nanayakkara, Michael Bennett, Rebecca Johnson, Catherine Meehan, Peter Colman

In 2015 the Australian Diabetes Society commissioned a working group to review and revise its position statement on scuba diving in persons with diabetes. The working group consisted of endocrinologists with an interest in type 1 diabetes, diving medical specialists, a recreational diver with diabetes and an advocate for people with type 1 diabetes.

A thorough literature review was performed and all available evidence was summarised and a new position statement was drafted. The new position statement was submitted to the ADS Council for approval.

The scope of this document is restricted to recreational (not professional) diving in line with the available evidence. It is also targeted at insulin-requiring (both type 1 and type 2) diabetes, as traditionally this group has been excluded from recreational diving. This document updates the ADS position statement in line with current evidence.

Download the full version of the ADS Insulin-requiring diabetes and recreational diving Position Statement - PDF and Appendicies - PDF (Posted: December, 2016)


ADS launches T2D Treatment Website (A New Blood Glucose Management Algorithm for Type 2 Diabetes)

As part of World Diabetes Day (14 November, 2016), the Australian Diabetes Society has launched a new interactive website aimed at improving the lives of people living with type 2 diabetes.

The T2D treatment website is the first of its kind in Australia to offer health-care clinicians a user-friendly, interactive tool to assist them in determining the best treatment option for their patients.   The launch of the website follows the release of a revised position statement by the ADS entitled, ‘A new blood glucose management algorithm for type 2 diabetes’.

This initiative involved the support of groups including the National Association of Diabetes Centres (NADC), Diabetes Australia (DA), the National Prescribing Service (NPS) and the Royal Australian College of General Practitioners (RACGP).  

Please visit http://t2d.diabetessociety.com.au to access the T2D treatment website.

ADS Position Statement on A New Blood Glucose Management Algorithm for Type 2 Diabetes

The blood glucose management algorithm for type 2 diabetes outlines the risks, benefits and costs of available therapies and provides an approach for how to incorporate older and newer agents.

Control of blood glucose levels in people with type 2 diabetes has clear benefits for preventing microvascular complications and potential benefits for reducing macrovascular complications and death.

Treatment needs to be individualised for the person with diabetes.

This should start with selection of the appropriate blood glucose and HbA1c targets, taking into account life expectancy and the wishes of the person with diabetes. A range of recently available therapies have added to our range of options for controlling blood glucose levels but this has made the clinical pathway for managing diabetes more complicated.

To assist with clinical decision making, in 2014 the Australian Diabetes Society council appointed an expert working group to draft a position statement with a focus on the results of recent randomised clinical trials. The original statement was reviewed by the ADS council (September 2014) and then sent to all ADS members for comment before publication in the Medical Journal of Australia (December 2014). In light of new randomised clinical trial evidence the statement and algorithm was updated (December, 2016).

Download the updated (December, 2016) full version of the ADS A New Blood Glucose Management Algorithm for Type 2 Diabetes Position Statement - PDF (Posted: December, 2016)


Australasian Diabetes Data Network (ADDN)

The Australasian Diabetes Data Network (ADDN) is an initiative of the Juvenile Diabetes Research Foundation (JDRF) supported by the Australasian Paediatric Endocrine Group (APEG) and the Australian Diabetes Society (ADS) to build long term clinical research capacity in Australia for people with diabetes.

ADDN has established Australia’s first national clinical research diabetes database, collecting clinical information from people with type 1 diabetes and connecting the data on an integrated, secure, custom-built platform. This rich data resource includes national-level information about type 1 diabetes, available to researchers within strict ethical and governance boundaries.

The database currently contains clinical data from children and adolescents with diabetes from seven specialist paediatric public tertiary centres across Australia. With planned expansion to adult centres, ADDN will extend its data capture and provide richer and more complete information about the natural history, clinical progression and most effective treatment regimens for all people living with type 1 diabetes.

For more information, visit the ADDN website at http://www.addn.org.au/


Australian Obesity Management Algorithm

Obesity is a complex and multi-factorial chronic disease with genetic, environmental, physiological and behavioural determinants that requires long-term care. In 2014-15, 63.4% of Australians aged 18 years and over were above normal weight, with 27.9% being obese. Obesity is associated with a broad range of complications including type 2 diabetes, cardiovascular disease, dyslipidaemia, sleep apnoea, osteoarthritis, and certain types of cancers, which significantly impair quality of life. Obesity and its related complications place a considerable financial burden on Australia. In 2014-15, the direct and indirect costs of obesity were estimated at $ 8.65 billion.

This statement has been developed by a working group with representatives from the Australian Diabetes Society, the Australian and New Zealand Obesity Society and the Obesity Surgery Society of Australian and New Zealand.

The aims of the document are to:

1) Assist general practitioners (GPs) in treatment decisions for non-pregnant adults with obesity

2) Provide a practical clinical tool to guide the implementation of existing guidelines for the treatment of obesity in the primary care setting in Australia.

Download the full version of the Australian Obesity Management Algorithm - PDF (Posted: October, 2016)


Important TGA Update
Below are the latest updates from the Therapeutic Goods Administration regarding the medicine shortage information of pioglitazone hydrochloride and gliclazide.
  • Medicine Shortage Information - Gliclazide 
  • Medicine Shortage Information - Pioglitazone Hydrochloride

     


    2019 ADS Membership

    The 2019 Australian Diabetes Society Membership Fee Renewals are now overdue. Please ensure that the ADS Secretariat has all the correct mailing and contact details, particularly email addresses, as we rely on these to maintain contact with you and keep you informed of ADS activities. The 2019 ADS Subscription period is from 1 July 2019 to 30 June 2020. Please contact the ADS secretariat at admin@diabetessociety.com.au for membership enquiries.


    Enhancing Your Consulting Skills - available for download online

    “Enhancing Your Consulting Skills: Supporting self-management and optimising mental health in people with type 1 diabetes” is designed for trainees in Adult Endocrinology, their supervisors and other interested health professionals. The resource includes topics such as information giving, health literacy, facilitating practical skills acquisition, and promoting behaviour change. It also explores the emotional, psychological and psychiatric issues that can impact on the quality of life of people with type 1 diabetes.

     

    “Enhancing Your Consulting Skills” was developed by the Australian Diabetes Society for the National Diabetes Services Scheme. It is now available in electronic format through the ADS website at: [http://diabetessociety.com.au/download-request.asp]. It can be downloaded free of charge for individual use. Please Note that you will be required to submit a request for download and obtain your password prior to receiving the download link. Hard copies of the resource are available from the ADS Secretariat.



    Important Information regarding changes to the National Diabetes Services Scheme

    From 1 July 2016 some important changes are happening to the National Diabetes services Scheme (NDSS). There are no changes to the types of products available under the NDSS, but the way people access these products may change. People will still be able to access NDSS products through their local participating community pharmacy access point. In fact the Federal Government wants to extend the number of community pharmacies that provide NDSS products to make it more convenient for people with diabetes. NDSS products will no longer be available through Diabetes Australia (DA) or state and territory diabetes organisations. This means people will no longer be able to order products via the Diabetes Australia shops, the NDSS 1300 number or via the website. Diabetes Australia and state and territory diabetes organisations will instead focus efforts on continuing to provide education services for people with diabetes. There will be no changes to NDSS education services funded by the Government - in fact the Government will be increasing funding to expand education and support available to people with diabetes. Community Pharmacies have made up more than 90% of all NDSS access points in Australia for over ten years, so people can be confident that if they have not accessed pharmacy before for this, they will receive a high level of service.

    Please visit the Department of Health website for the latest updates or click here to read the NDSS Frequently Asked Questions.


    Australian National Diabetes Strategy 2016-2020

    The Australian Government has developed and released a new National Diabetes Strategy to update and priorities the national response to diabetes across all levels of government. The Australian National Diabetes Strategy 2016-2020 (the Strategy) is a high-level document that contains a number of goals and potential areas for action that provide a range of ideas for implementation to achieve each goal. This presents a range of opportunities for jurisdictions to partner with the Commonwealth to develop and support approaches for diabetes prevention and control. The Strategy was endorsed by the Australian Health Ministers Advisory Council (AHMAC) on 2 October 2015, noted by the COAG Health Council on 6 November 2015, and publically released 13 November 2015. An implementation plan will be developed in consultation with jurisdictions through AHMAC to consider the ways to direct funding and other resources and proposed measures to evaluate the progress of the Strategy. Engagement and support from jurisdictions will facilitate a coordinated approach to diabetes across governments and ensure there is broad benefit from the Strategy. The Strategy has been informed by the expert advice of the National Diabetes Strategy Advisory Group and consultations with key stakeholders and the community. The Australian Government provides support to people with diabetes through Medicare and a range of programs and this new Strategy will not replace or override existing processes. This Strategy aims to better coordinate health resources across the sector to where they are needed most. The Australian National Diabetes Strategy document is available from the Department of Health's website at http://www.health.gov.au/internet/main/publishing.nsf/Content/nds-2016-2020 Media Release Statement by Health Minister; the Hon Sussan Ley MP on Australia delivers new National Diabetes Strategy on World Diabetes Day


    The Australian Diabetes Society endorses Endocrinology, Diabetes & Metabolism Case Reports

    Endocrinology, Diabetes & Metabolism Case Reports is a unique, open access resource that publishes and links together case reports, enabling practitioners to communicate findings, share knowledge and convey medical experiences efficiently and effectively; furthering both medical education and clinical practice. The search and browse functionality enables fluid navigation between case reports, facilitating discovery, connections and comparisons; making it the go-to resource across all the many disciplines intersecting with endocrinology, diabetes and metabolism.

    Members of the Australian Diabetes Society receive a 20% discount on the open access publishing charge when publishing case reports in Endocrinology, Diabetes & Metabolism Case Reports (submit online via www.edmcasereports.com).

    Please click on the PDF link to download and view the member flyer - PDF


    Updated Medical Standards from 1 October 2016
    While many factors contribute to safety on the road, driver health and fitness to drive is an important consideration. Drivers must meet certain medical standards to ensure their health status does not unduly increase their crash risk. Assessing Fitness to Drive, a joint publication of Austroads and the National Transport Commission (NTC), details the medical standards for driver licensing for use by health professionals and driver licensing authorities. The standards are approved by Commonwealth, state and territory transport ministers. In October 2016, new medical standards come into effect for drivers of private and commercial vehicles. The NTC website provides information for health professionals, employers, heavy vehicle drivers, commercial drivers and private vehicle drivers. Please click on the link to download the free electronic pdf version at https://www.onlinepublications.austroads.com.au/items/AP-G56-16